<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331666</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR1041</org_study_id>
    <nct_id>NCT03331666</nct_id>
  </id_info>
  <brief_title>Impact of LDL-cholesterol Lowering on Platelet Activation</brief_title>
  <official_title>Impact of LDL-cholesterol Lowering on Platelet Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal is to assess the impact of Evolocumab therapy on platelet function of
      familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab
      is a humanized monoclonal antibody that targets circulating PCSK9, increases hepatic LDL
      receptor, decreases plasma LDL cholesterol and reduces risk of cardiovascular events.
      Evolocumab (brand name Rapatha) has been approved by FDA along with diet and maximally
      tolerated statin therapy in adults with FH or atherosclerotic heart or blood vessel problems,
      who need additional lowering of LDL cholesterol.

      The secondary goal is to determine if platelet activation or the response to Evolocumab
      therapy is modified by rs3184504 polymorphism. The investigators believe that these
      investigations will complement ongoing studies to demonstrate that Evolocumab reduces
      athero-thrombotic risk and aid the decision-making as to whether Evolocumab can reduce the
      atherothrombotic risk in ACS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlipidemia as exemplified by familial hypercholesterolemia is associated with increased
      platelet activation and an underlying pro-coagulant state. Hyperlipidemia primes platelets
      and increases platelet activation in response to various agonists. Plasma cholesterol levels
      appear to have a critical role in modulating platelet activity as hypercholesterolemia
      increases platelet activation more potently than hypertriglyceridemia. Increased platelet
      reactivity may contribute to the increased risk of atherothrombosis associated with
      hypercholesterolemia. Plasma levels of platelet activation markers such as
      thrombin-antithrombin complex (TAT), soluble P-selectin (sP-selectin), soluble CD40L (sCD40L)
      or P-selectin exposure at surface of platelets are increased in hypercholesterolemic
      patients. Increased levels of the platelet activation markers are associated with increased
      platelet membrane cholesterol content in hypercholesterolemia.Statins may show antithrombotic
      properties.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in P2Y12 Reaction Units</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 88</time_frame>
    <description>ADP-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 assay (Accriva Diagnostics) will be performed. Unit: PRU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in platelet P-selectin level</measure>
    <time_frame>Day 7, Day 14, Day 21, Day 28, Day 88</time_frame>
    <description>Platelet activation measured by flow cytometry or commercially-available enzyme-linked immunoassays (ELISAs). Reported as % positive cells (out of 50,000 cells counted) showed a mean reduction ± standard deviation (SD)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 88.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 88.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>REPATHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have a clinical diagnosis of familial hypercholesterolemia (FH)

          -  Subjects who are referred to Dr. Ginsberg's Lipid Practice for treatment with PCSK9
             inhibitor

          -  Subjects with LDL cholesterol levels &gt;100 mg/dl on baseline treatment with statins
             and/or ezitimibe

        Exclusion Criteria:

          -  Children under 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Ginsberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nan Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nan Wang, PhD</last_name>
    <phone>212-342-1761</phone>
    <email>nw30@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lilian Oling, MA</last_name>
    <phone>212-305-9851</phone>
    <email>lao2106@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nan Wang, PhD</last_name>
      <phone>212-342-1761</phone>
      <email>nw30@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wei Wang, PhD</last_name>
      <phone>212-305-6596</phone>
      <email>ww2351@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nan Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med. 1974 Feb 21;290(8):434-8.</citation>
    <PMID>4359434</PMID>
  </reference>
  <reference>
    <citation>CONNOR WE, HOAK JC, WARNER ED. Massive thrombosis produced by fatty acid infusion. J Clin Invest. 1963 Jun;42:860-6.</citation>
    <PMID>14022629</PMID>
  </reference>
  <reference>
    <citation>Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.</citation>
    <PMID>22214850</PMID>
  </reference>
  <reference>
    <citation>Harmon JT, Tandon NN, Hoeg JM, Jamieson GA. Thrombin binding and response in platelets from patients with dyslipoproteinemias: increased stimulus-response coupling in type II hyperlipoproteinemia. Blood. 1986 Aug;68(2):498-505. Review.</citation>
    <PMID>3524709</PMID>
  </reference>
  <reference>
    <citation>Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol. 1993 Oct;44(2):112-6.</citation>
    <PMID>8266915</PMID>
  </reference>
  <reference>
    <citation>Davì G, Romano M, Mezzetti A, Procopio A, Iacobelli S, Antidormi T, Bucciarelli T, Alessandrini P, Cuccurullo F, Bittolo Bon G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998 Mar 17;97(10):953-7.</citation>
    <PMID>9529262</PMID>
  </reference>
  <reference>
    <citation>Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001 Nov 13;104(20):2395-400.</citation>
    <PMID>11705814</PMID>
  </reference>
  <reference>
    <citation>Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 2002 Dec;32(12):901-8.</citation>
    <PMID>12534449</PMID>
  </reference>
  <reference>
    <citation>Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013 Jan 15;127(2):251-7. doi: 10.1161/CIRCULATIONAHA.112.145334. Review.</citation>
    <PMID>23319813</PMID>
  </reference>
  <reference>
    <citation>Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.</citation>
    <PMID>16226162</PMID>
  </reference>
  <reference>
    <citation>Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davì G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002 Jul 23;106(4):399-402.</citation>
    <PMID>12135935</PMID>
  </reference>
  <reference>
    <citation>Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. Epub 2006 Aug 14.</citation>
    <PMID>16907931</PMID>
  </reference>
  <reference>
    <citation>Pawelczyk M, Chmielewski H, Kaczorowska B, Przybyła M, Baj Z. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci. 2015 Mar 16;11(1):115-21. doi: 10.5114/aoms.2015.49216. Epub 2015 Mar 14.</citation>
    <PMID>25861297</PMID>
  </reference>
  <reference>
    <citation>Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation. 2012 Jul 3;126(1):92-103. doi: 10.1161/CIRCULATIONAHA.112.095554. Epub 2012 May 21.</citation>
    <PMID>22615342</PMID>
  </reference>
  <reference>
    <citation>Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.</citation>
    <PMID>24678979</PMID>
  </reference>
  <reference>
    <citation>Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.</citation>
    <PMID>25773607</PMID>
  </reference>
  <reference>
    <citation>Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1.</citation>
    <PMID>27046161</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv. 2013 Feb;6(2):169-79. doi: 10.1016/j.jcin.2012.09.013.</citation>
    <PMID>23428009</PMID>
  </reference>
  <reference>
    <citation>Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. J Thromb Thrombolysis. 2014 May;37(4):427-34. doi: 10.1007/s11239-013-0966-0.</citation>
    <PMID>23852152</PMID>
  </reference>
  <reference>
    <citation>Sikora J, Kostka B, Marczyk I, Krajewska U, Chałubiński M, Broncel M. Effect of statins on platelet function in patients with hyperlipidemia. Arch Med Sci. 2013 Aug 30;9(4):622-8. doi: 10.5114/aoms.2013.36905. Epub 2013 Aug 8.</citation>
    <PMID>24049520</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Nan Wang</investigator_full_name>
    <investigator_title>Associate Professor of Medical Sciences (in Medicine) at the Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>Hyperlipidemia, Hypercholesterolemia, atherothrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

